Characteristics | N = 36 |
---|---|
Age, years (median [range]) | 51 (31–77) |
< 65, n (%) | 33 (91.7) |
≥ 65, n (%) | 3 (8.3) |
Menopausal status, n (%) | |
Postmenopausal | 26 (72.2) |
Premenopausal | 10 (27.8) |
ECOG PS, n (%) | |
0 | 23 (63.9) |
1 | 12 (33.3) |
2 | 1 (2.8) |
Time since 1st BC diagnosis to study inclusion, years (median [range]) | 4 (1–37) |
Time since M1 diagnosis to study inclusion, years (median [range]) | 2 (0.2–14) |
Number of metastatic locations, n (%) | |
1 | 9 (25.0) |
2 | 14 (38.9) |
≥ 3 | 13 (36.2) |
Metastatic locations, n (%) | |
Visceral | 28 (77.8) |
• Liver | 25 (69.4) |
• Lung | 7 (19.4) |
• Adrenal gland, pericardial effusion, or pleural involvement | 6 (16.6) |
Non-visceral only | 8 (22.2) |
• Bone | 20 (55.6) |
• Breast | 2 (5.6) |
• Lymph nodes | 13 (36.1) |
• Skin | 4 (11.1) |
• Soft tissue | 5 (13.9) |
Histological type, n (%) | |
Invasive ductal carcinoma | 33 (91.7) |
Invasive lobular carcinoma | 2 (5.6) |
Invasive squamous carcinoma | 1 (2.8) |
Histological grade, n (%) | |
1 | 1 (2.8) |
2 | 14 (38.9) |
3 | 16 (44.4) |
Unknown | 5 (13.9) |
HR status (local), n (%) | |
Negative | 21 (58.3) |
Positive | 15 (41.7) |
Ki67 expression (local) (%) | |
Median (range) | 30 (15–95) |
< 20%, n (%) | 5 (13.9) |
≥ 20%, n (%) | 21 (58.3) |
Unknown | 10 (27.8) |
BC subtype by IHC (local), n (%) | |
TN | 21 (58.3) |
HR-positive disease | 15 (41.7) |
Prior therapy, n (%) | |
CT | 36 (100.0) |
• ABC | 34 (94.4) |
ET | 26 (72.2) |
• ABC | 19 (52.8) |
BT | 25 (69.4) |
• ABC | 24 (66.7) |
Number of prior lines for ABC, n (%) | |
None | 1 (2.8) |
1 | 9 (25.0) |
2 | 2 (5.6) |
3 | 3 (8.3) |
4 | 5 (13.9) |
5 | 7 (19.4) |
≥ 6 | 9 (25.0) |
Median (range) | 4 (0–11) |
• TN | 2 (1–8) |
• HR-positive disease | 5 (3–11) |